UNICYCIVE THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate
UNICYCIVE THERAPEUTICS, INC. (UNCY) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate of 108.49% for the 3-month period ending 2025-03-31, per its 10-Q filed 2026-05-12.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate · last filed 2026-05-12
- UNICYCIVE THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2025-03-31 was 108.49%, a 1.89% increase year-over-year.
- UNICYCIVE THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2024-03-31 was 106.48%.
- UNICYCIVE THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2020 was 114.00%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 12 month |
|---|---|---|---|---|
| 2025-03-31 | 108.49% 10-Q · filed 2026-05-12 | |||
| 2024-06-30 | 104.00% 10-Q · filed 2025-08-14 | |||
| 2024-03-31 | 106.48% 10-Q · filed 2024-05-13 | |||
| 2022-06-30 | 101.00% 10-Q · filed 2023-08-14 | |||
| 2020-12-31 | 114.00% 10-K · filed 2022-03-31 | |||
| 2020-09-30 | 114.00% 10-Q · filed 2021-11-12 | |||
| 2020-06-30 | 114.00% 10-Q · filed 2021-08-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |